BioSpace News Archive

LENSAR, Inc. today announced that the Company’s fourth quarter and full year 2023 financial results will be released before market open on Monday, March 4, 2024.

UroGen Pharma Ltd. today announced that it will present at TD Cowen’s 44th Annual Health Care Conference on Monday, March 4, 2024 at 1:30pm EST.

Hoth Therapeutics, Inc. announced today that it has completed bioanalytical method development under its prior agreement with Altasciences and plans to further engage Altasciences to perform a key study of mouse blood and plasma analysis from samples collected in Hoth’s sponsored scientific research conducted at NC State University.

Alpha Tau Medical Ltd. today announced that management will participate at the Barclays 26th Annual Global Healthcare Conference on March 12th and 13th, 2024.

Inozyme Pharma, Inc. today announced Douglas A. Treco, Ph.D., the Company’s chief executive officer and chairman of the board, will participate in an Orphan Bone & Neuromuscular Diseases panel presentation at the TD Cowen 44th Annual Health Care Conference.

LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW ) (“LIXTE” or the “Company”) today announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each a component of the National Institute of Health (NIH).

Tenaya Therapeutics, Inc. today announced the publication of preclinical research related to Tenaya’s small molecule inhibitors of histone deacetylase 6 (HDAC6).

NRx Pharmaceuticals (Nasdaq:NRXP) Launches HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024.

Agiliti Inc. announced that it has entered into a definitive merger agreement pursuant to which an affiliate of private equity firm Thomas H. Lee Partners, L.P., the company’s majority shareholder, will acquire all outstanding shares of Agiliti common stock not currently owned by THL and its affiliates and certain management shareholders for $10.00 per share in cash, implying an enterprise value of approximately $2.5 billion.

People who are suffering from fibromyalgia pain are closer to a new option for treatment that targets their characteristically poor sleep quality.